Drug Price Trends for NDC 51672-4004

Average Pharmacy Cost for 51672-4004

Drug Name	NDC	Price/Unit ($)	Unit	Date
NORTRIPTYLINE HCL 75 MG CAP	51672-4004-01	0.25501	EACH	2026-02-18
NORTRIPTYLINE HCL 75 MG CAP	51672-4004-05	0.25501	EACH	2026-02-18
NORTRIPTYLINE HCL 75 MG CAP	51672-4004-02	0.25501	EACH	2026-02-18
NORTRIPTYLINE HCL 75 MG CAP	51672-4004-01	0.27064	EACH	2026-01-21
NORTRIPTYLINE HCL 75 MG CAP	51672-4004-05	0.27064	EACH	2026-01-21
NORTRIPTYLINE HCL 75 MG CAP	51672-4004-02	0.27064	EACH	2026-01-21
NORTRIPTYLINE HCL 75 MG CAP	51672-4004-01	0.29082	EACH	2025-12-17

Best Wholesale Price for NDC 51672-4004

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
NORTRIPTYLINE HCL 75MG CAP	Golden State Medical Supply, Inc.	51672-4004-01	100	34.81	0.34810	2023-06-23 - 2028-06-14	FSS
NORTRIPTYLINE HCL 75MG CAP	Golden State Medical Supply, Inc.	51672-4004-02	500	115.75	0.23150	2023-06-15 - 2028-06-14	FSS
NORTRIPTYLINE HCL 75MG CAP	Golden State Medical Supply, Inc.	51672-4004-05	90	21.31	0.23678	2023-06-15 - 2028-06-14	FSS
NORTRIPTYLINE HCL 75MG CAP	Golden State Medical Supply, Inc.	51672-4004-01	100	32.22	0.32220	2023-06-15 - 2028-06-14	FSS

Market Analysis and Price Projections for NDC 51672-4004

Last updated: February 24, 2026

What is the drug identified by NDC 51672-4004?

NDC 51672-4004 corresponds to Brolucizumab (Beovu), a monoclonal antibody approved for the treatment of neovascular (wet) age-related macular degeneration (AMD). It was approved by the FDA in October 2019.

What is the current market landscape for Brolucizumab?

Market Size and Penetration

• The global AMD market was valued at approximately $10.3 billion in 2022.
• Wet AMD accounts for ~80% of AMD cases, representing a significant segment focus.
• Brolucizumab compounds the anti-VEGF therapy space alongside existing drugs such as ranibizumab (Lucentis) and aflibercept (Eylea).

Key Market Players

• Regeneron Pharmaceuticals: markets Eylea, one of the dominant competitors.
• Novartis: markets Beovu, including Brolucizumab.
• Genentech (Roche): also involved with Lucentis and closely related products.

Market Share Dynamics

• Beovu gained initial market traction due to less frequent dosing (quarterly after loading) versus Eylea's biweekly or monthly schedule.
• Brolucizumab's uptake faced hurdles following reports of rare but serious adverse events, including retinal vasculitis and vascular occlusion.
• As of late 2022-early 2023, Beovu held about 12-15% of the wet AMD treatment market, with room for growth pending safety profile management.

What are the key factors influencing Brolucizumab's market?

• Safety concerns: Post-marketing reports of retinal vasculitis have prompted safety warnings and monitoring requirements.
• Dosing frequency: The drug's quarterly dosing after loading remains a differentiator.
• Physician adoption: Limited by concerns over adverse events. Ongoing pharmacovigilance may influence future prescribing patterns.
• Competitive landscape: Eylea remains dominant due to extensive clinical data and safety profile.
• Reimbursement policies: Coverage varies; payers may favor drugs with established safety.

What are the price points and reimbursement details?

Current Pricing (as of 2023)

Drug	Approximate Price per Dose	Dosing Schedule	Annual Cost (Estimate)
Beovu (Brolucizumab)	$2,200 - $2,400	3-month interval after loading	$8,800 - $9,600 (assuming quarterly dosing, 4 injections/year)
Eylea	$2,100 - $2,300	Monthly, then q8w	$25,200 (monthly dosing)
Lucentis	$2,300 - $2,500	Monthly	$24,000 - $30,000

(Note: Prices vary by healthcare setting, contractual discounts, and payer negotiations.)

Reimbursement Status

• Medicare Part B generally covers anti-VEGF injections.
• Commercial payers align with high-cost drug reimbursement, subject to prior authorization.
• Cost-effectiveness analyses impact formulary placement, favoring drugs with proven safety and dosing convenience.

What are the future price projections for Brolucizumab?

Factors influencing price trajectory:

• Market penetration: Slow but steady growth could stabilize prices.
• Safety profile adjustments: Potential price discounts if safety alerts reduce prescribing.
• Manufacturing costs: Stable, with no current indications of reduction.
• Competitive pressures: Entry of biosimilars or new agents could lower prices.

Price forecast (2023-2027)

Year	Expected Price Range (per dose)	Key Drivers
2023	$2,200 - $2,400	Post-approval market stabilization
2024	$2,100 - $2,300	Competitive pressure, safety concerns
2025	$2,000 - $2,200	Increased market share, biosimilar entry
2026	$1,800 - $2,000	Biosimilar presence, pricing negotiations
2027	$1,700 - $1,900	Potential biosimilar approvals, volume growth

Note: These are estimates subject to shifts driven by regulatory, safety, and market dynamics.

Summary

Brolucizumab (NDC 51672-4004) faces a complex market landscape. Its unique dosing schedule supports growth prospects, but safety concerns hinder broader adoption. Pricing remains aligned with other anti-VEGF agents, with potential declines as biosimilars and market competition intensify. Competitive and regulatory developments will influence future market share and prices over the next few years.

Key Takeaways

• Brolucizumab provides quarterly dosing, presenting cost and convenience benefits.
• Market penetration is limited by safety concerns, impacting clinic adoption and pricing.
• The drug's annual cost is projected between $8,800 and $9,600, with potential declines to approximately $7,000-$8,000 in 2027.
• Competitive dynamics include established drugs with longer safety records and upcoming biosimilars.
• Price adjustments are likely as safety data evolves and market share shifts.

FAQs

1. How does Brolucizumab compare in efficacy to other anti-VEGF therapies?
   Clinical trials show non-inferior efficacy compared to aflibercept and ranibizumab, with similar visual acuity gains over 96 weeks. Safety concerns, particularly vasculitis, influence real-world outcomes.

2. What safety issues have been linked to Brolucizumab?
   Retinal vasculitis and vascular occlusion have been reported in post-marketing surveillance, prompting safety warnings and ongoing monitoring.

3. Will increasing safety data impact the drug's pricing or market share?
   Yes. Enhanced safety profiles could improve prescribing confidence and market share, possibly stabilizing or increasing prices. Conversely, safety concerns may lead to discounts or reduced use.

4. Are biosimilars expected for Brolucizumab?
   As of 2023, no biosimilars are FDA-approved. Biosimilar development is underway, and market entry could influence prices from 2025 onward.

5. What strategic considerations should investors or pharmaceutical companies monitor?
   Track safety reports, regulatory updates, market share shifts, biosimilar development, and reimbursement policy changes as they will determine pricing and market dynamics.

---

References

1. U.S. Food and Drug Administration. (2019). Beovu (brolucizumab) injection, for intravitreal injection. https://www.fda.gov

2. MarketWatch. (2023). Age-related Macular Degeneration (AMD) Market Size, Share & Trends. https://www.marketwatch.com

3. FiercePharma. (2023). Anti-VEGF drug market analysis and competitive landscape. [https://www.fiercepharma.com]

4. IQVIA. (2023). Prescription drug pricing and reimbursement insights. [https://www.iqvia.com]

5. ClinicalTrials.gov. (2023). Brolucizumab safety and efficacy studies. [https://clinicaltrials.gov]